Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation

医学 拜瑞妥 阿哌沙班 达比加群 依杜沙班 心房颤动 危险系数 冲程(发动机) 内科学 华法林 重症监护医学 置信区间 机械工程 工程类
作者
Wallis C. Y. Lau,Carmen Olga Torre,Kenneth K. C. Man,Henry Morgan Stewart,Sarah Seager,Mui Van Zandt,Christian Reich,Jing Li,Jack Brewster,Gregory Y.H. Lip,Aroon D. Hingorani,Li Wei,Ian C. K. Wong
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:175 (11): 1515-1524 被引量:43
标识
DOI:10.7326/m22-0511
摘要

Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.To do a large-scale comparison between all DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) in routine clinical practice.Multinational population-based cohort study.Five standardized electronic health care databases, which covered 221 million people in France, Germany, the United Kingdom, and the United States.Patients who were newly diagnosed with AF from 2010 through 2019 and received a new DOAC prescription.Database-specific hazard ratios (HRs) of ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), gastrointestinal bleeding (GIB), and all-cause mortality between DOACs were estimated using a Cox regression model stratified by propensity score and pooled using a random-effects model.A total of 527 226 new DOAC users met the inclusion criteria (apixaban, n = 281 320; dabigatran, n = 61 008; edoxaban, n = 12 722; and rivaroxaban, n = 172 176). Apixaban use was associated with lower risk for GIB than use of dabigatran (HR, 0.81 [95% CI, 0.70 to 0.94]), edoxaban (HR, 0.77 [CI, 0.66 to 0.91]), or rivaroxaban (HR, 0.72 [CI, 0.66 to 0.79]). No substantial differences were observed for other outcomes or DOAC-DOAC comparisons. The results were consistent for patients aged 80 years or older. Consistent associations between lower GIB risk and apixaban versus rivaroxaban were observed among patients receiving the standard dose (HR, 0.72 [CI, 0.64 to 0.82]), those receiving a reduced dose (HR, 0.68 [CI, 0.61 to 0.77]), and those with chronic kidney disease (HR, 0.68 [CI, 0.59 to 0.77]).Residual confounding is possible.Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
4秒前
125ljw发布了新的文献求助10
4秒前
lsy完成签到,获得积分10
5秒前
5秒前
粗犷的沛容应助liuliliu采纳,获得10
6秒前
6秒前
yao发布了新的文献求助10
6秒前
漂泊1991完成签到,获得积分10
7秒前
木亢应助caixiayin采纳,获得100
7秒前
CipherSage应助呵呵心情采纳,获得10
8秒前
彩色橘子发布了新的文献求助10
9秒前
Tony发布了新的文献求助10
10秒前
赘婿应助ze采纳,获得10
11秒前
12秒前
sword完成签到,获得积分10
12秒前
wanglongjun发布了新的文献求助10
12秒前
14秒前
14秒前
14秒前
科目三应助SXM采纳,获得10
14秒前
彭于晏应助Cyril采纳,获得10
14秒前
theonePTC发布了新的文献求助10
15秒前
16秒前
段落落完成签到,获得积分10
17秒前
Tony完成签到,获得积分10
17秒前
可乐发布了新的文献求助10
18秒前
18秒前
XOO关闭了XOO文献求助
19秒前
研友_VZG7GZ应助叛逆阿周采纳,获得10
19秒前
卷卷完成签到,获得积分10
19秒前
笨笨的弱发布了新的文献求助10
20秒前
嗯qq发布了新的文献求助10
20秒前
wanglongjun完成签到,获得积分10
21秒前
咸鱼完成签到,获得积分10
21秒前
呵呵心情发布了新的文献求助10
21秒前
22秒前
23秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 600
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3064564
求助须知:如何正确求助?哪些是违规求助? 2719276
关于积分的说明 7463160
捐赠科研通 2365657
什么是DOI,文献DOI怎么找? 1254139
科研通“疑难数据库(出版商)”最低求助积分说明 608796
版权声明 596684